{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:46:30Z","timestamp":1791395190748,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1245\/s10434-020-08355-3","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T18:03:44Z","timestamp":1584381824000},"page":"2348-2356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phase 2 Trial of Adjuvant Chemotherapy With S\u2009\u2212\u20091 for Node-Positive Biliary Tract Cancer (N-SOG 09)"],"prefix":"10.1245","volume":"27","author":[{"given":"Kazuaki","family":"Seita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kurumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"8355_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","volume":"258","author":"M Nagino","year":"2013","unstructured":"Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129\u201340.","journal-title":"Ann Surg."},{"key":"8355_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/bjs.10452","volume":"104","author":"K Komaya","year":"2017","unstructured":"Komaya K, Ebata T, Shirai K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426\u201333.","journal-title":"Br J Surg."},{"key":"8355_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.surg.2017.08.011","volume":"163","author":"K Komaya","year":"2018","unstructured":"Komaya K, Ebata T, Yokoyama Y, et al. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery. 2018;163:732\u20138.","journal-title":"Surgery."},{"key":"8355_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","volume":"221","author":"B Groot Koerkamp","year":"2015","unstructured":"Groot Koerkamp B, Wiggers JK, Allen PJ, et al. Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg. 2015;221:1041\u20139.","journal-title":"J Am Coll Surg."},{"key":"8355_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s00268-007-9173-5","volume":"31","author":"T Ebata","year":"2007","unstructured":"Ebata T, Nagino M, Nishio H, Igami T, Yokoyama Y, Nimura Y. Pancreatic and duodenal invasion in distal bile duct cancer: paradox in the tumor classification of the American Joint Committee on Cancer. World J Surg. 2007;31:2008\u201315.","journal-title":"World J Surg."},{"key":"8355_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/SLA.0b013e3182822277","volume":"257","author":"T Aoba","year":"2013","unstructured":"Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg. 2013;257:718\u201325.","journal-title":"Ann Surg."},{"key":"8355_CR7","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1245\/s10434-016-5243-y","volume":"23","author":"N Amini","year":"2016","unstructured":"Amini N, Kim Y, Wilson A, et al. Prognostic implications of lymph node status for patients with gallbladder cancer: a multi-institutional study. Ann Surg Oncol. 2016;23:3016\u201323.","journal-title":"Ann Surg Oncol."},{"key":"8355_CR8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jamasurg.2016.1769","volume":"151","author":"F Giuliante","year":"2016","unstructured":"Giuliante F, Ardito F, Guglielmi A, et al. Association of lymph node status with survival in patients after liver resection for hilar cholangiocarcinoma in an Italian multicenter analysis. JAMA Surg. 2016;151:916\u201322.","journal-title":"JAMA Surg."},{"key":"8355_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/bjs.9752","volume":"102","author":"M Kiriyama","year":"2015","unstructured":"Kiriyama M, Ebata T, Aoba T, et al. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg. 2015;102:399\u2013406.","journal-title":"Br J Surg."},{"key":"8355_CR10","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934\u201340.","journal-title":"J Clin Oncol."},{"key":"8355_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192\u2013202.","journal-title":"Br J Surg."},{"key":"8355_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658\u201367.","journal-title":"J Clin Oncol."},{"key":"8355_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373.","journal-title":"Lancet Oncol."},{"key":"8355_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1470-2045(19)30022-1","volume":"20","author":"D Malka","year":"2019","unstructured":"Malka D, Edeline J. Adjuvant capecitabine in biliary tract cancer: a standard option? Lancet Oncol. 2019;20:606\u20138.","journal-title":"Lancet Oncol."},{"key":"8355_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol."},{"key":"8355_CR16","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1200\/JCO.2010.31.0326","volume":"28","author":"I Okamoto","year":"2010","unstructured":"Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010;28:5240\u20136.","journal-title":"J Clin Oncol."},{"key":"8355_CR17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/bjc.2012.86","volume":"106","author":"I Mochizuki","year":"2012","unstructured":"Mochizuki I, Takiuchi H, Ikejiri K, et al. Safety of UFT\/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. Br J Cancer. 2012;106:1268\u201373.","journal-title":"Br J Cancer."},{"key":"8355_CR18","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/sj.bjc.6602208","volume":"91","author":"H Ueno","year":"2004","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004;91:1769\u201374.","journal-title":"Br J Cancer."},{"key":"8355_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849\u201355.","journal-title":"Cancer Chemother Pharmacol."},{"key":"8355_CR20","volume-title":"Internatinal Union Against Cancer TNM Classification of Malignant Tumours","author":"LH Sobin","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. Internatinal Union against cancer TNM classification of malignant tumours. 7th ed. New Jersey: Wiley-Blackwell; 2009.","edition":"7"},{"key":"8355_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/sj.bjc.6602804","volume":"93","author":"M Tsukuda","year":"2005","unstructured":"Tsukuda M, Kida A, Fujii M, et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer. 2005;93:884\u20139.","journal-title":"Br J Cancer."},{"key":"8355_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3892\/mco.2015.500","volume":"3","author":"T Yamatsuji","year":"2015","unstructured":"Yamatsuji T, Fujiwara Y, Matsumoto H, et al. Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S-1 administration followed by 2-week rest vs 2-week administration followed by 1-week rest. Mol Clin Oncol. 2015;3:527\u201332.","journal-title":"Mol Clin Oncol."},{"key":"8355_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/jjco\/hyw062","volume":"46","author":"J Soh","year":"2016","unstructured":"Soh J, Okumura N, Nakata M, et al. Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. Jpn J Clin Oncol. 2016;46:741\u20137.","journal-title":"Jap J Clin Oncol."},{"key":"8355_CR24","unstructured":"Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009. Retrieved 27 November 2019 at https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"8355_CR25","first-page":"201","volume":"237","author":"Y Tojima","year":"2003","unstructured":"Tojima Y, Nagino M, Ebata T, Uesaka K, Kamiya J, Nimura Y. Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with otherwise node-negative hilar cholangiocarcinoma. Ann Surg. 2003;237:201\u20137.","journal-title":"Ann Surg."},{"key":"8355_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/01.sla.0000217675.22495.6f","volume":"244","author":"E Sasaki","year":"2006","unstructured":"Sasaki E, Nagino M, Ebata T, et al. Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with gallbladder carcinoma. Ann Surg. 2006;244:99\u2013105.","journal-title":"Ann Surg."},{"key":"8355_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/bjs.9379","volume":"101","author":"T Ebata","year":"2014","unstructured":"Ebata T, Kosuge T, Hirano S, et al. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg. 2014;101:79\u201388.","journal-title":"Br J Surg."},{"key":"8355_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/bjs.10556","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Mizuno T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg. 2018;105:829\u201338.","journal-title":"Br J Surg."},{"key":"8355_CR29","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1245\/s10434-019-07457-x","volume":"26","author":"Y Toyoda","year":"2019","unstructured":"Toyoda Y, Ebata T, Mizuno T, et al. Cholangiographic tumor classification for simple patient selection prior to hepatopancreatoduodenectomy for cholangiocarcinoma. Ann Surg Oncol. 2019;26:2971\u20139.","journal-title":"Ann Surg Oncol."},{"key":"8355_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00595-016-1354-0","volume":"47","author":"T Mizuno","year":"2017","unstructured":"Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score-matching analysis. Surg Today. 2017;47:182\u201392.","journal-title":"Surg Today."},{"key":"8355_CR31","first-page":"230","volume":"270","author":"S Kobayashi","year":"2018","unstructured":"Kobayashi S, Nagano H, Tomokuni A, et al. A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208). Kansai Hepato-Biliary Oncology Group. Ann Surg. 2018;270:230\u20137.","journal-title":"Kansai Hepato-Biliary Oncology Group. Ann Surg."},{"key":"8355_CR32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med."},{"key":"8355_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/annonc\/mdy282","volume":"29","author":"D Sakai","year":"2018","unstructured":"Sakai D, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann. Oncol. 2018;29:205.","journal-title":"Ann. Oncol."},{"key":"8355_CR34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/jjco\/hyy004","volume":"48","author":"K Nakachi","year":"2018","unstructured":"Nakachi K, Konishi M, Ikeda M, et al. A randomized Phase III trial of adjuvant S-1 therapy vs observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018;48:392\u20135.","journal-title":"Jap J Clin Oncol."},{"key":"8355_CR35","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1016\/j.ejca.2013.07.003","volume":"49","author":"JA Ajani","year":"2013","unstructured":"Ajani JA, Buyse M, Lichinitser M, et al. Combination of cisplatin\/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin\/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013;49:3616\u201324.","journal-title":"Eur J Cancer."},{"key":"8355_CR36","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","volume":"26","author":"DG Haller","year":"2008","unstructured":"Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26:2118\u201323.","journal-title":"J Clin Oncol."},{"key":"8355_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","volume":"102","author":"B Chuah","year":"2011","unstructured":"Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102:478\u201383.","journal-title":"Cancer Sci."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-020-08355-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-08355-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:24:21Z","timestamp":1615854261000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-020-08355-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["8355"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-08355-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Masahiko Ando has received grants from Kyowa Kirin Co. Ltd. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}